维得利珠单抗、抗肿瘤坏死因子或常规治疗下炎症性肠病患者的妊娠结局:欧洲CONCEIVE研究结果
本研究为回顾性多中心病例对照观察性研究,评估维得利珠单抗暴露妊娠(VDZE)的妊娠及子代结局,并与抗TNF暴露(TNFE)及未暴露免疫调节剂和生物制剂(CON IBD)的妊娠比较。VDZE组79例妊娠,TNFE组186例,CON IBD组184例。各组流产率、活产儿胎龄、出生体重、早产率、先天畸形率、母乳喂养率及婴儿第一年感染风险均无显著差异。结论认为VDZE妊娠未检测到新的安全性信号,但需更大规模前瞻性研究确认。
要点
- VDZE组妊娠期疾病活动比例较高(36%),但流产率与对照组无显著差异。
- 活产儿胎龄、出生体重、Apgar评分、早产率及先天畸形率组间相似。
- 婴儿第一年无恶性肿瘤报告,感染风险组间无显著差异。
核心结论
- 维得利珠单抗暴露妊娠未检测到新的安全性信号,但需更大规模前瞻性研究确认。
研究设计与样本
- 回顾性多中心病例对照观察性研究,VDZE组79例妊娠(73例IBD女性),TNFE组186例妊娠(164例IBD女性),CON IBD组184例妊娠(155例IBD女性)。
主要发现
- 活产儿中位胎龄、出生体重、Apgar评分、早产率、先天畸形率及母乳喂养率组间相似。
- 婴儿第一年无恶性肿瘤报告,感染风险组间无显著差异。
临床怎么用
- 对于妊娠期需要生物制剂维持缓解的IBD女性,维得利珠单抗暴露未显示增加不良妊娠或子代结局风险。
局限性
- 本研究为回顾性设计,样本量有限,需更大规模前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse. AIMS: To assess pregnancy and child outcomes of VDZE pregnancies and to compare these results to anti-TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies. METHODS: A retrospective multicentre case-control observational study was performed. RESULTS: VDZE group included 79 pregnancies in 73 IBD women. The TNFE and CON IBD group included 186 pregnancies (162 live births) in 164 IBD women and 184 pregnancies (163 live births) in 155 IBD women, respectively. At conception, cases more often had active disease ([VDZE: 36% vs TNFE: 17%, P = .002] and [VDZE: 36% vs CON IBD: 24%, P = .063]). No significant difference in miscarriage rates were found between groups (VDZE and TNFE: 16% vs 13%, P = .567; VDZE and CON IBD: 16% vs 10%, P = .216). In live-born infants, median gestational age and birthweight were similar between groups. Median Apgar score at birth was numerically equal. Prematurity was similar in the VDZE group compared to the control groups, even when correcting for disease activity during pregnancy. The frequency of congenital anomalies was comparable between groups as were the percentages of breastfed babies. During the first year of life, no malignancies were reported and infants' infection risk did not significantly differ between groups. CONCLUSION: No new safety signal was detected in VDZE pregnancies although larger, prospective studies are required for confirmation.
引用
- Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2019. PMID: 31692017. doi:10.1111/apt.15539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。